CanBas Co., Ltd.

TSE:4575 Stock Report

Market Cap: JP¥10.4b

CanBas Past Earnings Performance

Past criteria checks 0/6

CanBas's earnings have been declining at an average annual rate of -15.8%, while the Biotechs industry saw earnings growing at 13.7% annually. Revenues have been declining at an average rate of 93.7% per year.

Key information

-15.80%

Earnings growth rate

3.82%

EPS growth rate

Biotechs Industry Growth31.91%
Revenue growth rate-93.68%
Return on equity-57.84%
Net Marginn/a
Next Earnings Update12 Aug 2026

Recent past performance updates

Recent updates

Analysis Article May 20

Is CanBas (TSE:4575) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article Feb 03

We Think CanBas (TSE:4575) Can Easily Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article Apr 08

CanBas (TSE:4575) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article Dec 16

Here's Why We're Not Too Worried About CanBas' (TSE:4575) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article Jun 26

CanBas (TSE:4575) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article Feb 26

We're Hopeful That CanBas (TSE:4575) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Revenue & Expenses Breakdown

How CanBas makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TSE:4575 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 260-1,1992070
31 Dec 250-1,2452040
30 Sep 250-1,2091970
30 Jun 250-1,1571940
31 Mar 250-1,4871940
31 Dec 240-1,2961900
30 Sep 240-1,3111910
30 Jun 240-1,2091910
31 Mar 240-1,0862100
31 Dec 230-1,0742050
30 Sep 230-1,1161960
30 Jun 230-1,2441840
31 Mar 230-9831820
31 Dec 220-1,0591760
30 Sep 220-9791760
30 Jun 220-8551750
31 Mar 2226-7331850
31 Dec 2153-5801830
30 Sep 2181-5191820
30 Jun 21108-5311740
31 Mar 21110-5481790
31 Dec 20110-6101760
30 Sep 20110-6371780
30 Jun 20110-5721860
31 Mar 20109-5161840
31 Dec 19109-5711800
30 Sep 19109-4921660
30 Jun 19115-4561610
31 Mar 19116-4861720
31 Dec 18116-4351800
30 Sep 18116-5081890
30 Jun 18110-5321910
31 Mar 18109-5281970
31 Dec 17109-4631930
30 Sep 17109-4151930
30 Jun 17109-4191900
31 Mar 17110-3741960
31 Dec 16110-4851880
30 Sep 16107-4801730
30 Jun 16105-4141670
31 Mar 16101-3841820
31 Dec 1599-2551790
30 Sep 1585-2561820
30 Jun 1560-2661780

Quality Earnings: 4575 is currently unprofitable.

Growing Profit Margin: 4575 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 4575 is unprofitable, and losses have increased over the past 5 years at a rate of 15.8% per year.

Accelerating Growth: Unable to compare 4575's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4575 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3.9%).


Return on Equity

High ROE: 4575 has a negative Return on Equity (-57.84%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/11 21:19
End of Day Share Price 2026/06/11 00:00
Earnings2026/03/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CanBas Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kiyokazu YamazakiIchiyoshi Research Institute Inc.